X
API Suppliers
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
Talzenna (talazoparib) is a PARP inhibitor, which is approved for the treatment of BRCA gene mutation-positive castration-resistant prostate cancer with distant metastases.
Lead Product(s): Talazoparib
Therapeutic Area: Oncology Product Name: Talzenna
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 05, 2024
Details:
Talzenna (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor in combination with Xtandi (enzalutamide) is approved by EMA for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC).
Lead Product(s): Talazoparib,Enzalutamide
Therapeutic Area: Oncology Product Name: Talzenna
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 08, 2024
Details:
Talzenna (talazoparib) is an oral inhibitor of PARP, which plays a role in DNA damage repair combination with XTANDI (enzalutamide) for the treatment of adult patients with homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC).
Lead Product(s): Talazoparib,Enzalutamide
Therapeutic Area: Oncology Product Name: Talzenna
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: TFS Trial Form Support
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 20, 2023
Details:
Talzenna (talazoparib) is an oral PARP inhibitor, which plays a role in DNA damage repair. Preclinical studies have demonstrated that TALZENNA blocks PARP enzyme activity and traps PARP at the site of DNA damage, leading to cancer cell apoptosis.
Lead Product(s): Talazoparib,Enzalutamide
Therapeutic Area: Oncology Product Name: Talzenna
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 16, 2023
Details:
CX-5461 (pidnarulex) stabilizes the DNA G-quadruplexes of cancer cells which leads to disruption of the cell's replication fork. Pidnarulex demonstrated clinically significant and lasting benefits in patients with specific tumor biomarkers, such as BRCA1/2 and PALB2 mutations.
Lead Product(s): Pidnarulex,Talazoparib
Therapeutic Area: Oncology Product Name: CX-5461
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 31, 2022
Details:
TALZENNA® (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor met its primary endpoint with a statistically significant and clinically meaningful improvement in radiographic progression-free survival (rPFS) compared with placebo plus XTANDI.
Lead Product(s): Talazoparib,Enzalutamide
Therapeutic Area: Oncology Product Name: Talzenna
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 04, 2022
Details:
ART4215 is first selective, oral, small molecule inhibitor of Polθ polymerase domain to enter clinic. Polθ, a DNA polymerase, is a tumor-specific DDR target involved in MMEJ that is overexpressed in many tumors and found in low levels in healthy tissue.
Lead Product(s): ART4215,Talazoparib
Therapeutic Area: Oncology Product Name: ART4215
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 10, 2022
Details:
ZEN-3694 (ZEN003694), orally bioavailable small molecule, in initro studies selectively binds to BET proteins with >20 fold selectivity over non-BET bromodomains inhibiting interaction of acetylated histone peptide with IC50 values in low nM range.
Lead Product(s): ZEN003694,Talazoparib
Therapeutic Area: Oncology Product Name: ZEN-3694
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: National Cancer Institute
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 06, 2022
Details:
The combination regimen of ZEN-3694 (ZEN003694) + talazoparib has shown promising clinical activity in a mTNBC patient population with significant unmet need. This combination is active with a manageable safety profile and warrants continued clinical evaluation.
Lead Product(s): ZEN-3694,Talazoparib
Therapeutic Area: Oncology Product Name: ZEN003694
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 21, 2022
Details:
CX-5461 (Pidnarulex) demonstrated clinically significant and persist benefits in patients with specific tumor biomarkers, such as BRCA1/2, and PALB2 mutations, and who had been exposed to platinum and other chemotherapeutics.
Lead Product(s): Pidnarulex,Talazoparib
Therapeutic Area: Oncology Product Name: CX-5461
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Pfizer Inc
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 06, 2022
Details:
The data from the Phase 1b/2 trial has shown that the ZEN003694 (ZEN-3694) plus talazoparib combination regimen induced durable responses in tumors of TNBC patients which do not harbor mutations in BRCA1/2.
Lead Product(s): ZEN-3694,Talazoparib
Therapeutic Area: Oncology Product Name: ZEN003694
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Pfizer Inc
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 10, 2022
Details:
RP-3500 is a potent and selective oral small molecule inhibitor of ATR being developed for treatment of solid tumors with specific genome instability related genomic alterations including those in the ATM (ataxia-telangiectasia mutated) gene.
Lead Product(s): Camonsertib,Talazoparib,Gemcitabine
Therapeutic Area: Oncology Product Name: RP-3500
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 08, 2022
Details:
RP-3500, orally-administered ataxia telangiectasia and Rad3-related inhibitor currently in Phase 1/2 TRESR trial clinical development in patients with DNA damage repair, loss-of-function and mutant tumors.
Lead Product(s): Camonsertib,Talazoparib,Gemcitabine
Therapeutic Area: Oncology Product Name: RP-3500
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 08, 2022
Details:
Dose optimization provides robust evidence to advance RP-3500, a potent and selective oral small molecule inhibitor of ATR into Phase 2 studies with a recommended dose and schedule, for the treatment of solid tumors.
Lead Product(s): Camonsertib,Talazoparib,Gemcitabine
Therapeutic Area: Oncology Product Name: RP-3500
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 07, 2022
Details:
Pidnarulex synthetically derived small molecule in combination with Talazoparib (PARP inhibitor), potential therapy in patients with metastatic castration-resistant prostate cancer.
Lead Product(s): Pidnarulex,Talazoparib
Therapeutic Area: Oncology Product Name: CX-5461
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Peter MacCallum Cancer Centre
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 22, 2021
Details:
RP-3500 is a potent and selective oral small molecule inhibitor of ATR being developed for the treatment of solid tumors with selected genomic alterations.
Lead Product(s): Camonsertib,Talazoparib
Therapeutic Area: Oncology Product Name: RP-3500
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 29, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
